Login to Your Account



Other News To Note


Wednesday, September 12, 2012
• Compugen Ltd., of Tel Aviv, Israel, said mode-of-action studies on protein drug candidate CGEN-15001 demonstrated active suppression of pathogenic immune responses and reestablishment of immune balance by increasing anti-inflammatory mediators and promoting inducible regulatory T cells, considered a promising approach to treat autoimmune disease and cancer.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription